Incannex Healthcare (IXHL) EBITDA (2022 - 2026)

Incannex Healthcare has disclosed EBITDA across 5 years of filings, most recently posting -$4.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$4.4 million, down 7.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$48.6 million (down 125.38% YoY), and the FY2025 annual result was -$46.7 million, down 151.82% from the prior year.
• EBITDA came in at -$4.4 million for Q1 2026 at Incannex Healthcare, up from -$6.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $766000.0 in Q4 2022 to a low of -$31.3 million in Q2 2025.
• The 5-year median for EBITDA is -$4.7 million (2024), against an average of -$6.4 million.
• Across the five-year window, EBITDA plunged 663.19% in 2023 and surged 40.8% in 2025, its largest moves.
• Incannex Healthcare's EBITDA stood at $766000.0 in 2022, then slumped by 663.19% to -$4.3 million in 2023, then plunged by 46.22% to -$6.3 million in 2024, then decreased by 7.93% to -$6.8 million in 2025, then soared by 36.09% to -$4.4 million in 2026.
• The last three EBITDA figures came in at -$4.4 million (Q1 2026), -$6.8 million (Q4 2025), and -$6.2 million (Q3 2025), per Business Quant data.